SDMA-Symmetric-dimethylarginine-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁
SDMA-Symmetric-dimethylarginine-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁
SDMA-Symmetric-dimethylarginine-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁
SDMA-Symmetric-dimethylarginine-DataSheet-生命科學(xué)試劑-MedChemExpress_第4頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認(rèn)領(lǐng)

文檔簡介

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemESDMACat.No.:HY-101410CASNo.:30344-00-4Synonyms:Symmetricdimethylarginine;NG,NG'-Dimethyl-L-arginine分?式:C?H??N?O?分?量:202.25作?靶點:EndogenousMetabolite作?通路:MetabolicEnzyme/Protease儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:67.5mg/mL(333.75mM;Needultrasonic)H2O:50mg/mL(247.22mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制備儲備液1mM4.9444mL24.7219mL49.4438mL5mM0.9889mL4.9444mL9.8888mL10mM0.4944mL2.4722mL4.9444mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;?旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限:-80°C,6months;-20°C,1month。-80°C儲存時,請在6個?內(nèi)使?,-20°C儲存時,請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液,再依次添加助溶劑:(為保證實驗結(jié)果的可靠性,澄的儲備液可以根據(jù)儲存條件,適當(dāng)保存;體內(nèi)實驗的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的?式助溶)1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(12.36mM);Clearsolution2.請依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(12.36mM);Clearsolution3.請依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:2.5mg/mL(12.36mM);Suspendedsolution;Needultrasonic4.請依序添加每種溶劑:PBSSolubility:120mg/mL(593.33mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性SDMA(Symmetricdimethylarginine)?氧化氮(NO)合酶活性的內(nèi)性抑制劑。IC50&TargetHumanEndogenousMetabolite體外研究SDMAisthestructuralisomerofthecardiovascularriskmarkerasymmetricdimethylarginine,asanendogenousmarkerofrenalfunction.SDMAdoesnotdirectlyinhibitNOSbutisacompetitorofargininetransport.SDMAisprimarilyeliminatedbyrenalexcretionandisapromisingendogenousmarkerofglomerularfiltrationrate[1].SDMAinhibitsdosedependentlytheNOsynthesisinintactendothelialcells,whereasithasnoeffectonproteinexpressionofNOS[1].SDMAisinvolvedintheinflammatoryprocessofchronickidneydisease,activatingNF-κBandresultinginenhancedexpressionofIL-6andTNF-α[2].體內(nèi)研究SDMAishighlystableinserumandplasma,andtheassaydemonstratesexcellentanalyticalperformance.Inunaffecteddogs,SDMAremainsunchangedwhereasinaffecteddogs,SDMAincreasesduringdiseaseprogression,correlatingstronglywithanincreaseinsCranddecreaseinGFR[3].ChronicSDMAinfusionleadstoasignificantincreaseofSDMAlevelsinmice,buttheGFRdidnotchangeat4weeks.Nohistologicalchangesareobserved,particularlynoeffectonfibrosisorendotheliasnitricoxidesynthaseexpression.ThereisneitheraneffectofSDMAonsystolicbloodpressurenoronejectionfraction[4].PROTOCOLCellAssay[2]SDMAstocksolutionispreparedin0.9%NaClanddilutedinthecellculturemediumorinheparinizedwholebloodresultinginamaximaluremicconcentrationof6.1μMSDMA.Wholebloodisincubatedwithsaline(control)ordifferentdosesofADMA(0.6,3.6,and36μM)orSDMA(1.5,3.1,and6.1μM)for2hoursinahumidifiedatmosphereof5%CO2inairat37°C.CellsarefinallystainedforintracellularTNF-αorIL-6.Samplesareanalyzedwithaflowcytometer[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.AnimalMice:Eight-week-oldmaleC57Bl/6micereceivesvehicle-controlledinfusionofSDMA(250μmol/kg/days)forAdministration[4]28daysusingosmoticminipumps(n=24/group).Glomerularfiltrationrate,cardiacfunctionandbloodpressurearemonitored.BloodsamplesforSDMAdeterminationareobtainedatbaseline,2and4weeks.Miceareeuthanizedat4weekstoobtaintissueforrenalhistology[4].2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEMCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.REFERENCES[1].Bode-B?gerSM,etal.Symmetricaldimethylarginine:anewcombinedparameterforrenalfunctionandextentofcoronaryarterydisease.[2].SchepersE,etal.Symmetricdimethylarginineasaproinflammatoryagentinchronickidneydisease.ClinJAmSocNephrol.2011Oct;6(10):2374-83.[3].NabityMB,etal.SymmetricDimethylarginineAssayValidation,Stability,andEvaluationasaMarkerfortheEarlyDetectionofChronicKidneyDiseaseinDogs.JVetInternMed.2015Jul-Aug;29(4):1036-44.[4].VeldinkH,etal.EffectsofchronicSDMAinfusiononglomerularfiltrationrate,bloodpressure,myocardialfunctionandrenalhistologyinC57BL6/Jmice.NephrolDialTransplant.20

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論